X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (46770) 46770
Newspaper Article (8340) 8340
Newsletter (2943) 2943
Publication (2934) 2934
Magazine Article (691) 691
Book Review (589) 589
Trade Publication Article (247) 247
Book Chapter (175) 175
Conference Proceeding (54) 54
Transcript (50) 50
Dissertation (37) 37
Book / eBook (30) 30
Reference (29) 29
Web Resource (21) 21
Government Document (11) 11
Data Set (3) 3
Report (2) 2
Streaming Video (2) 2
Painting (1) 1
Paper (1) 1
Presentation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
aspirin (35627) 35627
humans (34255) 34255
aspirin - therapeutic use (18488) 18488
male (18256) 18256
female (18240) 18240
index medicus (14774) 14774
middle aged (12282) 12282
aged (11048) 11048
adult (8334) 8334
platelet aggregation inhibitors - therapeutic use (7870) 7870
risk factors (7841) 7841
cancer (7108) 7108
studies (6419) 6419
prevention (6261) 6261
health risk assessment (6001) 6001
animals (5666) 5666
aspirin - administration & dosage (5587) 5587
cardiac & cardiovascular systems (5446) 5446
aspirin - adverse effects (5335) 5335
risk (4760) 4760
treatment outcome (4705) 4705
stroke (4608) 4608
research (4389) 4389
aspirin - pharmacology (4366) 4366
clopidogrel (4278) 4278
mortality (4265) 4265
medicine, general & internal (4130) 4130
ticlopidine - analogs & derivatives (4080) 4080
drug therapy, combination (4052) 4052
pharmacology & pharmacy (3808) 3808
care and treatment (3628) 3628
peripheral vascular disease (3589) 3589
anticoagulants - therapeutic use (3518) 3518
drug therapy (3341) 3341
aged, 80 and over (3239) 3239
ticlopidine - therapeutic use (3216) 3216
time factors (3188) 3188
low-dose aspirin (3175) 3175
cardiovascular disease (3093) 3093
health aspects (3083) 3083
heart attacks (3050) 3050
analysis (2977) 2977
anti-inflammatory agents, non-steroidal - therapeutic use (2906) 2906
therapy (2879) 2879
hematology (2763) 2763
prospective studies (2720) 2720
surgery (2706) 2706
platelet aggregation inhibitors - administration & dosage (2662) 2662
thrombosis (2630) 2630
anticoagulants (2614) 2614
abridged index medicus (2605) 2605
medical research (2600) 2600
nonsteroidal antiinflammatory drugs (2591) 2591
platelet aggregation inhibitors - adverse effects (2486) 2486
pregnancy (2395) 2395
retrospective studies (2311) 2311
rats (2298) 2298
platelet aggregation - drug effects (2281) 2281
drug dosages (2275) 2275
dose-response relationship, drug (2255) 2255
follow-up studies (2224) 2224
fibrinolytic agents - therapeutic use (2175) 2175
anti-inflammatory agents, non-steroidal - adverse effects (2171) 2171
warfarin (2148) 2148
myocardial-infarction (2136) 2136
clinical trials as topic (2131) 2131
double-blind method (2094) 2094
dosage and administration (2033) 2033
disease (2032) 2032
drugs (2022) 2022
patients (1977) 1977
cardiology (1975) 1975
adolescent (1946) 1946
medicine & public health (1928) 1928
cardiovascular diseases (1885) 1885
oncology (1851) 1851
antiplatelet therapy (1824) 1824
risk assessment (1812) 1812
stroke - prevention & control (1785) 1785
acute coronary syndromes (1783) 1783
inflammation (1764) 1764
clinical neurology (1754) 1754
medicine, experimental (1723) 1723
randomized controlled trials as topic (1721) 1721
blood platelets (1714) 1714
clinical trials (1714) 1714
blood platelets - drug effects (1707) 1707
cardiac patients (1697) 1697
coronary heart disease (1679) 1679
nonsteroidal anti-inflammatory drugs (1673) 1673
trial (1653) 1653
management (1645) 1645
myocardial infarction - drug therapy (1603) 1603
usage (1593) 1593
warfarin - therapeutic use (1535) 1535
stents (1532) 1532
percutaneous coronary intervention (1531) 1531
recurrence (1511) 1511
gastroenterology & hepatology (1504) 1504
heparin - therapeutic use (1491) 1491
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (15) 15
Online Resources - Online (9) 9
Collection Dvlpm't (Acquisitions) - Closed Orders (2) 2
Collection Dvlpm't (Acquisitions) - Vendor file (2) 2
Chemistry (A D Allen) - Stacks (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (1) 1
UofT at Scarborough - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (55094) 55094
German (980) 980
French (837) 837
Spanish (407) 407
Russian (388) 388
Italian (314) 314
Japanese (272) 272
Chinese (176) 176
Polish (117) 117
Dutch (109) 109
Danish (61) 61
Portuguese (58) 58
Korean (50) 50
Norwegian (40) 40
Czech (34) 34
Swedish (34) 34
Finnish (32) 32
Hungarian (32) 32
Turkish (32) 32
Hebrew (21) 21
Romanian (19) 19
Serbian (18) 18
Ukrainian (17) 17
Croatian (15) 15
Bulgarian (12) 12
Lithuanian (9) 9
Slovak (9) 9
Persian (3) 3
Arabic (2) 2
Bosnian (2) 2
Afrikaans (1) 1
Catalan (1) 1
Hindi (1) 1
Icelandic (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2011, Volume 12, Issue 5, pp. 496 - 503
Summary In March, 2010, a group of breast cancer experts met to develop a consensus statement on breast cancer prevention, with a focus on medical and... 
Hematology, Oncology and Palliative Medicine | ZOLEDRONIC ACID | SURGICAL ADJUVANT BREAST | ONCOLOGY | STATIN USE | LOW-DOSE TAMOXIFEN | RANDOMIZED-TRIAL | FOLLOW-UP | RISK | BOWEL PROJECT | POSTMENOPAUSAL WOMEN | GENOME-WIDE ASSOCIATION | Thiophenes - therapeutic use | Metformin - therapeutic use | Raloxifene Hydrochloride - therapeutic use | Humans | Selective Estrogen Receptor Modulators - adverse effects | Tetrahydronaphthalenes - therapeutic use | Pyrrolidines - therapeutic use | Antineoplastic Agents, Hormonal - adverse effects | Aromatase Inhibitors - adverse effects | Estrogen Receptor Modulators - therapeutic use | Retinoids - therapeutic use | Selective Estrogen Receptor Modulators - therapeutic use | Antineoplastic Agents, Hormonal - therapeutic use | Diphosphonates - therapeutic use | Female | Aromatase Inhibitors - therapeutic use | Estrogen Receptor Modulators - adverse effects | Anticarcinogenic Agents - therapeutic use | Triazoles - therapeutic use | Premenopause | Anastrozole | Consensus Development Conferences as Topic | Breast Neoplasms - prevention & control | Fenretinide - therapeutic use | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Piperidines - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Tamoxifen - therapeutic use | Androstadienes - therapeutic use | Expert Testimony | Norpregnenes - therapeutic use | Nitriles - therapeutic use | COX-2 inhibitors | Care and treatment | Aspirin | Oncology, Experimental | Menopause | Phosphonates | Breast cancer | Retinoids | Research | Tamoxifen | Prevention | Analysis | Health aspects | Cancer
Journal Article
Journal Article
JAMA Neurology, ISSN 2168-6149, 12/2018, Volume 75, Issue 12, pp. 1511 - 1518
IMPORTANCE Non-vitamin K antagonist oral anticoagulants (NOACs) might be an attractive choice for stroke prevention in people without atrial fibrillation who... 
DABIGATRAN | SUBTYPES | RIVAROXABAN | EMBOLIC STROKE | LEFT ATRIAL ABNORMALITY | APIXABAN | CLINICAL NEUROLOGY | Heart | Anticoagulants | Medical research | Aspirin | Stroke | Warfarin | Clinical trials | Acetylsalicylic acid | Hemorrhage | Risk factors | Bleeding | Randomization | Fibrillation | Data collection | Drug therapy | Vitamin K | Online First | Original Investigation | Research
Journal Article
European Heart Journal, ISSN 0195-668X, 03/2003, Volume 24, Issue 5, pp. 464 - 474
Journal Article
Circulation, ISSN 0009-7322, 12/2010, Volume 122, Issue 24, pp. 2619 - 2633
proton pump inhibitors | antiplatelet drugs | gastrointestinal hemorrhage | platelet aggregation inhibitors | aspirin | thienopyridine | AHA Scientific Statements | CARDIAC & CARDIOVASCULAR SYSTEMS | CARDIOVASCULAR EVENTS | TRANSIENT ISCHEMIC ATTACK | ACID SUPPRESSION | ACUTE CORONARY SYNDROMES | H-2-RECEPTOR ANTAGONISTS | LOW-DOSE ASPIRIN | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | ACUTE MYOCARDIAL-INFARCTION | PERIPHERAL VASCULAR DISEASE | PLACEBO-CONTROLLED TRIAL | ST-SEGMENT ELEVATION | Piperazines - administration & dosage | Prasugrel Hydrochloride | Purinergic P2Y Receptor Antagonists - administration & dosage | Thiophenes - adverse effects | Cardiovascular Diseases - drug therapy | Humans | Thienopyridines - adverse effects | Thienopyridines - metabolism | Piperazines - metabolism | Thiophenes - metabolism | Thiophenes - administration & dosage | Aspirin - administration & dosage | Purinergic P2Y Receptor Antagonists - metabolism | Histamine H2 Antagonists - administration & dosage | Purinergic P2Y Receptor Antagonists - adverse effects | Drug Interactions | Proton Pump Inhibitors - administration & dosage | Aspirin - adverse effects | Aspirin - metabolism | Platelet Aggregation Inhibitors - administration & dosage | Ticlopidine - adverse effects | Ticlopidine - metabolism | Ticlopidine - administration & dosage | Anti-Inflammatory Agents, Non-Steroidal - metabolism | Platelet Aggregation Inhibitors - metabolism | Drug Therapy, Combination | Platelet Aggregation Inhibitors - adverse effects | Proton Pump Inhibitors - adverse effects | Thienopyridines - administration & dosage | Risk Factors | Histamine H2 Antagonists - adverse effects | Piperazines - adverse effects | Ticlopidine - analogs & derivatives | Aryl Hydrocarbon Hydroxylases - metabolism | Gastrointestinal Hemorrhage - chemically induced | Gastrointestinal Hemorrhage - prevention & control | Histamine H2 Antagonists - metabolism | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Cytochrome P-450 CYP2C19 | Anti-Inflammatory Agents, Non-Steroidal - administration & dosage | Proton Pump Inhibitors - metabolism
Journal Article
American Heart Journal, ISSN 0002-8703, 2014, Volume 168, Issue 5, pp. 611 - 621
Mortality and morbidity in acute coronary syndromes (ACSs), caused principally by plaque erosion or rupture leading to thrombus formation and myocardial... 
Cardiovascular | WORKING GROUP | CARDIAC & CARDIOVASCULAR SYSTEMS | ANTITHROMBOTIC THERAPY | DOUBLE-BLIND | ASSOCIATION TASK-FORCE | EUROPEAN-SOCIETY | ELEVATION MYOCARDIAL-INFARCTION | CONSENSUS DOCUMENT | PLATELET REACTIVITY | ATRIAL-FIBRILLATION | UNFRACTIONATED HEPARIN | Recombinant Proteins - therapeutic use | Prasugrel Hydrochloride | Thiophenes - therapeutic use | Hirudins | Humans | Heparin - therapeutic use | Enoxaparin - therapeutic use | Tyrosine - analogs & derivatives | Receptors, Thrombin - antagonists & inhibitors | Warfarin - therapeutic use | Tyrosine - therapeutic use | Adenosine - therapeutic use | Aspirin - therapeutic use | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Purinergic P2Y Receptor Antagonists - therapeutic use | Pyridines - therapeutic use | Polysaccharides - therapeutic use | Anticoagulants - therapeutic use | Piperazines - therapeutic use | Adenosine Monophosphate - therapeutic use | Lactones - therapeutic use | Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors | Acute Coronary Syndrome - drug therapy | Adenosine - analogs & derivatives | Adenosine Monophosphate - analogs & derivatives | Peptide Fragments - therapeutic use | Peptides - therapeutic use | Aspirin | Glycosaminoglycans | Atrial fibrillation | Mortality | Thrombin | Anticoagulants (Medicine) | Health aspects | Drug approval | Coronary heart disease | Heart attacks | Acute coronary syndromes | Drug therapy | Clinical outcomes | Kardiologi | Clinical Medicine | Cardiac and Cardiovascular Systems | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap
Journal Article
Circulation, ISSN 0009-7322, 08/2013, Volume 128, Issue 7, pp. 721 - 728
BACKGROUND—The role of concomitant aspirin (ASA) therapy in patients with atrial fibrillation (AF) receiving oral anticoagulation (OAC) is unclear. We assessed... 
Anticoagulants | Aspirin | Hemorrhage | Atrial fibrillation | Outcome assessment (health care) | PREDICTING STROKE | CARDIAC & CARDIOVASCULAR SYSTEMS | MANAGEMENT | METAANALYSIS | CARDIOVASCULAR EVENTS | GUIDELINES | ACUTE CORONARY SYNDROMES | ANTIPLATELET | atrial fibrillation | TASK-FORCE | WARFARIN | outcome assessment (health care) | anticoagulants | aspirin | PERIPHERAL VASCULAR DISEASE | PRIMARY PREVENTION | hemorrhage | Prospective Studies | Anticoagulants - administration & dosage | Follow-Up Studies | Ticlopidine - therapeutic use | Humans | Middle Aged | Hospitalization - statistics & numerical data | Male | Risk | Dabigatran | Hypertrophy, Left Ventricular - epidemiology | Aspirin - administration & dosage | Fibrinolytic Agents - adverse effects | Benzimidazoles - administration & dosage | Aspirin - adverse effects | Atrial Fibrillation - mortality | Registries - statistics & numerical data | Fibrinolytic Agents - therapeutic use | Platelet Aggregation Inhibitors - administration & dosage | Ticlopidine - adverse effects | Aged, 80 and over | Ticlopidine - administration & dosage | Female | Aspirin - therapeutic use | Cerebrovascular Disorders - epidemiology | Benzimidazoles - adverse effects | Platelet Aggregation Inhibitors - therapeutic use | beta-Alanine - analogs & derivatives | Benzimidazoles - therapeutic use | Myocardial Ischemia - epidemiology | Platelet Aggregation Inhibitors - adverse effects | beta-Alanine - adverse effects | Atrial Fibrillation - drug therapy | Comorbidity | Models, Cardiovascular | beta-Alanine - administration & dosage | beta-Alanine - therapeutic use | Anticoagulants - therapeutic use | Logistic Models | Treatment Outcome | Anticoagulants - adverse effects | Ticlopidine - analogs & derivatives | Drug Synergism | Aged | Fibrinolytic Agents - administration & dosage | Hemorrhage - chemically induced | Usage | Anticoagulants (Medicine) | Drug therapy | Health aspects
Journal Article
Nature Reviews Endocrinology, ISSN 1759-5029, 07/2016, Volume 12, Issue 7, pp. 381 - 393
Journal Article
Circulation, ISSN 0009-7322, 2015, Volume 131, Issue 17, pp. 1486 - 1494
Background Our aim was to describe the incidence and predictors of stroke in patients who have heart failure without atrial fibrillation (AF). Methods and... 
Heart failure | Stroke | Sinus rhythm | Atrial fibrillation | Risk factors | Ventricular ejection fraction | heart failure | risk factors | CARDIAC & CARDIOVASCULAR SYSTEMS | VENTRICULAR SYSTOLIC FUNCTION | RANDOMIZED-TRIAL | NATRIURETIC PEPTIDE | stroke | ASPIRIN | atrial fibrillation | CONVERTING-ENZYME INHIBITORS | THERAPY | WARFARIN | EJECTION FRACTION | ventricular ejection fraction | sinus rhythm | PERIPHERAL VASCULAR DISEASE | CANDESARTAN | THROMBOEMBOLISM | Follow-Up Studies | Humans | Middle Aged | Male | Diabetes Mellitus, Type 1 - complications | Peptide Fragments - blood | Aged, 80 and over | Adult | Female | Stroke - epidemiology | Natriuretic Peptide, Brain - blood | Benzimidazoles - therapeutic use | Heart Failure - complications | Stroke - prevention & control | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Rosuvastatin Calcium | Biomarkers - blood | Heart Failure - drug therapy | Randomized Controlled Trials as Topic | Stroke Volume | Cardiovascular Agents - therapeutic use | Stroke - etiology | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Atrial Fibrillation - etiology | Fatty Acids, Omega-3 - therapeutic use | Tetrazoles - therapeutic use | Aged | Fluorobenzenes - therapeutic use | Fatty Acids | Peptide Fragments/ blood | Omega-3/ therapeutic use | Tetrazoles/therapeutic use | Sulfonamides/ therapeutic use | Kardiologi | 80 and over | Biological Markers/blood | Natriuretic Peptide | Pyrimidines/ therapeutic use | Cardiovascular Agents/therapeutic use | Stroke/epidemiology/ etiology/prevention & control | Benzimidazoles/therapeutic use | Diabetes Mellitus | Type 1/complications | Brain/ blood | Cardiac and Cardiovascular Systems | Atrial Fibrillation/etiology | Fluorobenzenes/ therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors/ therapeutic use | Heart Failure/complications/ drug therapy
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 10/2008, Volume 52, Issue 18, pp. 1502 - 1517
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2008, Volume 359, Issue 12, pp. 1238 - 1251
In this large clinical trial, aspirin plus extended-release dipyridamole was found to have an efficacy similar to that of clopidogrel in the prevention of... 
ISSUES | MEDICINE, GENERAL & INTERNAL | PLACEBO | DESIGN | TICLOPIDINE | WARFARIN | TRANSIENT ISCHEMIC ATTACK | DOUBLE-BLIND | PREVENTION | REGIMENS | NON-INFERIORITY TRIALS | Myocardial Infarction - epidemiology | Benzoates - therapeutic use | Ticlopidine - therapeutic use | Humans | Middle Aged | Male | Risk | Secondary Prevention | Aspirin - administration & dosage | Vascular Diseases - mortality | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Aspirin - adverse effects | Platelet Aggregation Inhibitors - administration & dosage | Ticlopidine - adverse effects | Dipyridamole - adverse effects | Female | Stroke - epidemiology | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Dipyridamole - therapeutic use | Benzimidazoles - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Brain Ischemia - epidemiology | Stroke - prevention & control | Double-Blind Method | Kaplan-Meier Estimate | Proportional Hazards Models | Brain Ischemia - prevention & control | Factor Analysis, Statistical | Stroke - drug therapy | Ticlopidine - analogs & derivatives | Aged | Hemorrhage - chemically induced | Delayed-Action Preparations | Stroke (Disease) | Aspirin | Usage | Care and treatment | Dipyridamole | Clopidogrel | Health aspects | Stroke | Index Medicus | Abridged Index Medicus | Recurrence | Brain Ischemia | Benzimidazoles | Follow-Up Studies | Neurons and Cognition | Cognition | Hemorrhage | Drug Delivery Systems | Life Sciences | Angiotensin II Type 1 Receptor Blockers | Angiotensin-Converting Enzyme Inhibitors | Vascular Diseases | Mental Status Schedule | Retrospective Studies | Severity of Illness Index | Disability Evaluation | Benzoates | Drug Administration Schedule | International Cooperation | Ticlopidine | Myocardial Infarction | Platelet Aggregation Inhibitors | Santé publique et épidémiologie | Original | Dipyridamole/adverse effects/therapeutic use | Angiotensin-Converting Enzyme Inhibitors/therapeutic use | Recurrence/prevention & control | Benzoates/therapeutic use | Brain Ischemia/epidemiology/prevention & control | MEDICIN OCH HÄLSOVETENSKAP | Platelet Aggregation Inhibitors/administration & dosage/adverse | Combination | MEDICAL AND HEALTH SCIENCES | Aspirin/administration & dosage/adverse effects | Myocardial Infarction/epidemiology | Factor Analysis | Benzimidazoles/therapeutic use | Drug Therapy | Ticlopidine/adverse effects/analogs & derivatives/therapeutic use | effects/therapeutic use | Vascular Diseases/mortality | Hemorrhage/chemically induced | Stroke/drug therapy/epidemiology/prevention & control | Statistical | Kaplan-Meiers Estimate
Journal Article